Adherium Delivers First Order of Hailie Smart Inhaler Sensors to US Intermountain Health
Posted: 22 December 2023 Adherium Limited (ASX:ADR) a leader in digital health technologies has delivered the first purchase order agreement of 1,750 of its next generation Hailie® Smartinhaler® sensors to major US hospital system, Intermountain Health. This sale…
Preparing for Growth: Biointelect Appoints New CEO
Posted: 22 December 2023 Biointelect is delighted to wrap up 2023 by announcing the appointment of Leah Goodman as Chief Executive Officer. Leah will lead the organisation through its next exciting period of strategic growth cementing our unique…
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Posted: 22 December 2023 Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces constructive feedback has been received from the Paul-Ehrlich-Institut (“PEI”), a…
Positive DEP® docetaxel Phase 2 results
Posted: 20 December 2023 Starpharma today announces positive final results from the completed Phase 2 clinical program of DEP® docetaxel. The clinical program included a monotherapy arm and two combination arms. The Phase 2 trial objectives were met, with endpoints…
Neuren Ph2 trial shows significant improvements in Phelan-McDermid
Posted: 18 December 2023 Neuren Pharmaceuticals (ASX: NEU) today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Phelan-McDermid syndrome (PMS). Significant improvement was observed by both clinicians and caregivers from treatment, across…
Atmo Biosciences achieves patient recruitment target for dysmotility pivotal clinical study
Posted: 14 December 2023 More than 200 patients recruited in multi-site clinical trial to support a submission for initial U.S. regulatory clearance around the use of Atmo’s gas-sensing capsule to assess gastrointestinal motility disorders. Atmo Biosciences, a company…
Newborn medicine project celebrated by NHMRC as one of the best
Posted: 14 December 2023 The team behind a Murdoch Children’s Research Institute (MCRI) led project has been celebrated for their work in newborn medicine, aiming to improve the health outcomes of preterm and sick babies. Professor Lex Doyle and…
Key to fatty liver disease and its consequences for billions of people
Posted: 14 December 2023 The global rise in obesity and diabetes is leading to an epidemic in fatty liver disease affecting 20-30 per cent of the world’s population. Almost a third of people with fatty liver disease go…
MTPConnect Strengthens Life Science Links with South Korea Through MoU with Korea Health Industry Development Institute
Posted: 14 December 2023 With the execution of a new Memorandum of Understanding (MoU), MTPConnect and the Korea Health Industry Development Institute (KHIDI) have committed to working closely together to support the growth of health and medical technology,…
GMP Production of PAT-DX1 Next Quarter
Posted: 14 December 2023 Patrys is pleased to announce that its Contract Manufacturing and Development Oganisation (CDMO) has confirmed that a manufacturing slot for the GMP (Good Manufacturing Practice) production of PAT-DX1 will be available in Q1 CY…
Same destination, new crew for HSSA
Posted: 12 December 2023 Health Security Systems Australia (HSSA), a division of Australian public company DMTC Limited, has announced plans for the transiton of the division’s leadership. Dr Leigh Farrell, who has been involved with DMTC since 2015…
BACKING VICTORIAN MEDTECH BOOSTS BRAIN HEALTH, GROWS JOBS
Posted: 12 December 2023 Critical investment is accelerating the commercialisation of world-first Victorian technology to treat brain injuries, creating jobs at home and potentially benefiting patients around the globe. Minister for Economic Growth Tim Pallas today announced a…
